
Day 2 Recap: Elevate-Derm West 2024
Key Takeaways
- Pharmacokinetic modeling of spesolimab shows distinct profiles for intravenous and subcutaneous administration in generalized pustular psoriasis treatment.
- Systemic therapies for atopic dermatitis may enhance patient adherence compared to topical treatments, according to APP insights.
Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.
To stay informed with the latest conference insights,
Pharmacokinetic Modeling of Spesolimab Reveals Key Differences Between IV and Subcutaneous Dosing for Generalized Pustular Psoriasis
A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.
APP Insights Into AD Therapy: Systemics May Improve Patient Compliance
APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.
Pathology Wisdom for APPs: Lessons in Avoiding Common Diagnostic Challenges
Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.
“Is AI Coming for My Job?”: Familiarizing Clinicians with AI Tools and Their Role in Dermatology
In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.
Exploring Diet and New Treatments for Hidradenitis Suppurativa
From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.
To view all conference coverage from Elevate-Derm West 2024,
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















